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Cortical expression of the human angiotensinogen gene in the kidney of
transgenic mice. We have previously generated "Tsukuba hypertensive
mice" with elevated blood pressure by cross-mating separate lines of
transgenic animals carrying either 15 kb of the human renin gene including
its native 3-kb promoter or 14 kb of the human angiotensinogen gene
along with its 1.3-kb promoter, the former of which is expressed predom-
inantly in the kidney and the latter of which is also expressed in the kidney
to levels comparable to those found in the liver. To investigate whether the
integrated human angiotensinogen gene is prominently expressed in the
kidney of transgenic mice, we have analyzed a production region of the
transgene mRNA by in situ hybridization technique. This analysis clearly
demonstrated that human angiotensinogen mRNA is localized specifically
to the cortex region of transgenic mouse kidney. The present finding
indicates a possible involvement of the renal renin-angiotensin system in
the pathogenesis of high blood pressure in transgenic mice.
The renin-angiotensin system (RAS) plays a critically important
role in the regulation of cardiovascular and renal homeostasis [1].
The initiator enzyme renin, an aspartyl protease, is synthesized
mainly by the kidney and secreted into the circulation, where it
cleaves angiotensinogen, the only known in vivo substrate, pro-
duced by the liver, to form an inactive decapeptide angiotensin I
(Ang I). Through the action of angiotensin-converting enzyme
(ACE), Mg I is cleaved to form the biologically active octapep-
tide angiotensin II (Mg II), which functions as both a vasocon-
strictor and an effector of aldosterone release from the adrenal
gland. Although this cascade has long been believed to be an
endocrine system, a new idea has recently been proposed: the
paracrine-autocrine effects of locally acting RAS influence tissue
functions, independently of the circulating RAS. This idea is
supported by evidence derived from immunohistochemical, bio-
chemical and molecular biological demonstration of all compo-
nents of the RAS, including renin, angiotensinogen, ACE, Mg I,
Aug II and Ang II receptors in local tissues such as heart, blood
vessel, adrenal gland and kidney [2—4].
The significant role of the local RAS has been assessed by a
large number of experiments involving the use of primary cell
cultures, including vascular smooth muscle cells, adrenal granu-
losa cells and renal cells. Although the participation of the RAS in
several disease states, including hypertension, has long been
suspected, in vitro analyses fall short of being an accurate repre-
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sentation of hypertension in the living organism. For example,
tissue culture experiments cannot assess the influence of blood
supply along with various humoral and cell-mediated factors. To
overcome these limitations, many investigators have turned to the
transgenic animal, a system in which the action of RAS compo-
nents would be assessed in a living host capable of mounting a
physiologic response to the development of hypertension [5—8].
According to this experimental concept, several transgenic ani-
mals carrying the genes for the RAS components have been
generated and associated with hypertension [9—13].
We have previously produced "Tsukuba hypertensive mice"
[13, 14] with elevated blood pressure by cross-mating separate
lines of transgenic animals carrying either 15 kb of the human
renin gene including its native 3-kb promoter or 14 kb of the
human angiotensinogen gene along with its 1.3-kb promoter [15],
the former of which is expressed predominantly in the kidney
[16—18] and the latter of which is also expressed in the kidney to
levels comparable to those found in the liver [19]. In the present
study, as the first step to understand this unexpected renal
expression of the human angiotensinogen gene as well as the
consequence of overproduction of human renin and human
angiotensinogen in the kidney of hypertensive transgenic mice, we
have analyzed a production region of the human angiotensinogen
mRNA by in situ hybridization.
Methods
In situ hybridization
The 44-mer antisense oligonucleotides used as a probe specific
to human angiotensinogen mRNA were synthesized on a Cy-
clone Plus oligonucleotide DNA synthesizer (MilliGen/Biore-
search), and purified on OPC columns (Applied Biosystems,
Foster City, California, USA) as described by the manufacturer:
5'-CAAAGTCGACTCA'TTAGAAGAAAAGGTGGGAGACT-
GGGGGTGAC-3' (nucleotide positions, + 1598 to + 1641) [15].
The oligonucleotides were labeled with 35S-dATP using terminal
deoxyribonucleotidyl transferase (BRL).
Fresh frozen kidney section of the transgenic and nontransgenic
mice were prepared at a thickness of 20 m, and mounted on glass
slides precoated with 4% 3-aminopropyltriethoxysilane in aceton.
Following fixation with 4% paraformaldehyde for 10 minutes, the
sections were processed for acetylation, prehybridization and
dehydration as described previously [20]. Hybridization was done
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Fig. 1. Cortical distribution of human
angiotensinogen mRNA. The 44-mer antisense
oligonucleotide probe complementary to the
human angiotensinogen gene was hybridized to
renal sections from transgenic (A) and
nontransgenic (B) mice. Photographs in this
figure were negative image made from an x-ray
film autoradiogram.
Table 1. Tissue distribution of renin and angiotensinogen mRNAs
Tissues hRN
hRN
(TgM) mRN hAG
hAG
(TgM) niAG
Kidney +++ -i-++ +++ + +++ +
Liver — — — +++ +++ +++
Heart + + + + + +
Brain + + + + + +
Abbreviations are: hRN, human renin; mRN, mouse renin; hAG,
human angiotensinogen; mAO, mouse angiotensinogen; TgM, transgenic
mouse; —, not detected; +, weak expression; + + +, strong expression.
at 42°C for 10 hours in 50 l of a buffer containing 50%
formamide, 0.1 M Tris-HC1 (pH 7.5), 4 X standard saline citrate
(SSC), 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine
serum albumin, 2% sarkosyl, 250 sg/ml of heat-denatured salmon
sperm DNA, 10% dextran sulfate, 0.1 M dithiothreitol and 5 X i0
dpm of 35S-labeled oligonucleotide probe. The sections were
washed at room temperature for 40 minutes in 2 X SSC contain-
ing 0.1% sarkosyl and were washed twice at 55°C for 40 minutes
in 0.1 X SSC containing 0.1% sarkosyl. They were exposed to
Hyperfilm-f3 max (Amersham) for 17 days and were then dipped
in NTB2 nuclear track emulsion (Kodak) for 17 days.
Results
Our recent studies demonstrated that the angiotensinogen gene
is expressed in the human kidney with much lower levels than
those found in the human liver, the major production site of
angiotensinogen [21], but that its human mRNA is accumulated in
the kidney to levels comparable to those found in the liver of the
two independently-generated transgenic mouse lines carrying
approximately 200 copies of the angiotensinogen gene [19]. The
latter finding shows the deregulated expression of the human
angiotensinogen gene in transgenic mice (Table 1). To explain
these conflicting results, we have previously proposed the two
ideas: (1) Suppression of the human angiotensinogen gene expres-
sion in the kidney is usually maintained by a negative regulatory
sequence that is missing in the microinjected DNA fragment. (2)
A mouse negative regulatory factor (or factors) cannot recognize
the human gene sequences, resulting the high-level expression in
the transgenic mouse kidney [7]. In any case, there is a possibility
that the human transgene is prominently expressed in transgenic
kidney.
To examine the distribution of human angiotensinogen mRNA
in the kidney of transgenic mice, in sit-u hybridization histochem-
istry was performed. The 44-mer antisense oligonucleotides cor-
responding to the nucleotide positions from + 1598 to + 1641 of
the human angiotensinogen gene were used for in situ hybridiza-
tion as a probe and labeled with 35S-dATP using terminal
deoxyribonucleotidyl transferase, because this segment can com-
pletely distinguish between the human and mouse angiotensino-
gen sequences [22]. Figure 1 revealed that the strong signals are
detected predominantly in the renal cortex of transgenic mice
(Fig. 1A), but not in the control sections derived from nontrans-
genie mice (Fig. 1B). Although the cellular distribution of the
transgene mRNA in the kidney could not be well defined in detail
by the present in situ hybridization, an immunohistochemical
analysis using a monoclonal antibody specific for human angio-
tensinogen suggested that the transgene products are accumu-
lated in the proximal tubules of kidney, but not in the distal ones
(data not shown). These results indicated that expression of the
human angiotensinogen gene integrated into the mouse genome is
regulated in a region-specific manner.
Discussion
Since immunohistochemical detection of angiotensinogen was
not able to distinguish between contamination or uptake from
plasma and in situ synthesis, direct evidence for renal production
of angiotensinogen has been difficult to obtain. In the present
study, we have analyzed the distribution of human angiotensino-
gen mRNA in transgenic mice by in situ hybridization and clarified
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the cortical expression of the transgene. Recently, by means of in
situ hybridization, rat angiotensinogen mRNA is shown to be
localized predominantly in the proximal renal tubule [23], consis-
tent with our present results.
An early study has demonstrated that angiotensinogen mRNA
is accumulated in rat renal cortex and medulla in apparently equal
proportions, but that its accumulation in response to the sodium
diet is more sensitive in the cortex than in the medulla [24]. Our
preliminary observation, however, showed that expression of the
human angiotensinogen gene was not influenced by the sodium
diet in the kidney of transgenic mice (unpublished results). In
addition, we have previously indicated that an acute phase
reaction elicited by the combinatorial action of E. coli lipopoly-
saccharide with glucocorticoid elevates the hepatic levels of
mouse angiotensinogen mRNA, but not those of human mRNA
in transgenic mice [22]. Taken together, these findings suggest the
lack of regulatory elements responsible for the sodium balance or
acute phase reaction within the 14 kb transgene used for gener-
ating transgenic mice. Nevertheless, it should be noted that
expression of the human angiotensinogen gene in the transgenic
kidney is regulated in a cortex-specific manner.
The concept of an intrarenal HAS for regulation of local kidney
function is particularly attractive, because the biologically active
final product of RAS, Ang II, has multiple action on renal
function, including cellular injury [4, 25]. In fact, our preliminary
pathological examination found organized fibrinoid necrosis of
small artery and glomerular sclerosis in the kidney of Tsukuba
hypertensive mice bearing both human renin and human angio-
tensinogen genes (data not shown). Although such renal failure is
usually considered to result from the secondary effect of sustained
high blood pressure, it is interesting to speculate that an excess of
Ang II produced from the overexpressed human renin and human
angiotensinogen within the kidney might be partially contributed
to the pathogenesis of renal injury in Tsukuba hypertensive mice.
In this sense, the present result provides an important implication
of the RAS in the intrarenal function.
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